Medpacto Is A Genomebased Drug Discovery And Clinical Stagebiotechnology Company That Is Pursuing Thedevelopment Of First In Class Therapies To Bring New Hopeto Patients Suffering From Themost Challenging Diseases Such As Cancertheleading Drug Candidateis Vactosertiban Orally Bioavailablesmall Moleculeinhibitor Of Thetgf I Typei Receptorti Ricurrently In Phasea I Clinical Trials With Global Pharmaceutical Companies Such As Merck And Astrazenecavactosertib Inhibits Transforming Growth Factor Betatgf I Pathway Signalingwhich Is Known To Promotethemetastasis And Proliferation Of Cancer Cells By Modulating Thetumor Microenvironmentvactosertib Plays A Synergistic Rolein Improving Theresponseto Various Therapies By Inhibiting Immunesuppressivetgf I Activity And Suppressing Theresistancemechanism Of Cancer Stem Cellsmedpacto Is Currently Conducting Combination Trials With Vactosertib Targeting Several Cancer Indications Including Colorectal Cancerpancreatic Cancersarcomasnsclcbladder Cancerand Gastric Canceradditionallymedpacto Is Currently Developing Mp005Aa New Antibody Therapeutics Targeting Bag2 Protein Which Promotes Tumor Formation And Lung Metastasis By Binding Theenzymes That Regulatethetumor Microenvironment In Cancer Developmentand Mp005Da Diagnostic Kit That Can Detect Bag2 Genes
